Patrizia Pulitano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patrizia Pulitano has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Biagio Maria Sancetta
Research Unit of Neurology, Department of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
2 shared publications - Giovanni Assenza
Research Unit of Neurology, Department of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
2 shared publications - Lorenzo Ricci
Research Unit of Neurology, Department of Medicine and Surgery Università Campus Bio‐Medico di Roma Rome Italy
2 shared publications - Mario Tombini
Department of Medicine and Surgery, Research Unit of Neurology, Neurobiology, Neurophysiology University Campus Bio‐Medico di Roma Rome Italy
2 shared publications - Vincenzo Di Lazzaro
Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
2 shared publications - Alessandra Morano
Department of Human Neurosciences Sapienza University Rome Italy
1 shared publication
Latest Publications
- Open Access
Predicting levetiracetam neuropsychiatric adverse effects using graph‐theoretical electroencephalographic network metrics in drug‐naive focal epilepsy: A multicenter longitudinal study
Objective: Levetiracetam (LEV) is an antiseizure medication approved for focal and generalized epilepsy. Despite its efficacy, neuropsychiatric adverse effects (NP‐AEs) may lead to treatment discontinuation. Quantitative electroencephalographic (qEEG) graph‐theoretical analysis has emerged as a valuable tool for identifying neurophysiological markers of treatment response. We investigated whether baseline network metrics could identify drug‐naive people with focal epilepsy (PwE) at risk of developing clinically significant LEV‐related NP‐AEs. Methods: We conducted a multicenter retrospective longitudinal study across three Italian centers. From an original LEV monotherapy cohort of 134 PwE, we identified all 31 eligible patients who developed clinically significant LEV‐related NP‐AEs within the first month after LEV initiation (AE+) and matched them by age and sex with 31 patients without NP‐AEs (AE−). All participants underwent resting‐state EEG within 30 days before LEV. We compared relative power spectral density (PSD) and weighted phase lag index (wPLI) connectivity‐derived graph‐theoretical metrics (clustering coefficient, global efficiency, path length, modularity, node strength) using linear mixed‐effects models. Baseline variables showing significant between‐group differences were included in an elastic‐net penalized logistic regression model. Model performance was evaluated using nested cross‐validation and permutation testing (1000 permutations). Results: Relative PSD showed no differences between groups. The AE+ group showed higher baseline theta‐band wPLI‐derived clustering coefficient ( p = .032), characteristic path length ( p = .033), and node strength ( p = .03) than AE−. In the elastic net model, theta‐band graph‐theoretical metrics predicted NP‐AE occurrence with an accuracy of .71 (95% confidence interval [CI] = .60–.82) and an area under the curve of .71 (95% CI = .57–.83). Permutation testing confirmed that model discrimination exceeded chance level ( p = .003). Significance: Baseline theta‐band qEEG functional network organization emerged as a significant neurophysiological predictor of LEV‐related NP‐AEs. These findings suggest that pretreatment EEG may capture a neurophysiological vulnerability phenotype associated with LEV tolerability, supporting the potential role of network‐level biomarkers in guiding individualized treatment decisions.
Open AccessPredicting levetiracetam neuropsychiatric adverse effects using graph‐theoretical electroencephalographic network metrics in drug‐naive focal epilepsy: A multicenter longitudinal study
Objective: Levetiracetam (LEV) is an antiseizure medication approved for focal and generalized epilepsy. Despite its efficacy, neuropsychiatric adverse effects (NP‐AEs) may lead to treatment discontinuation. Quantitative electroencephalographic (qEEG) graph‐theoretical analysis has emerged as a valuable tool for identifying neurophysiological markers of treatment response. We investigated whether baseline network metrics could identify drug‐naive people with focal epilepsy (PwE) at risk of developing clinically significant LEV‐related NP‐AEs. Methods: We conducted a multicenter retrospective longitudinal study across three Italian centers. From an original LEV monotherapy cohort of 134 PwE, we identified all 31 eligible patients who developed clinically significant LEV‐related NP‐AEs within the first month after LEV initiation (AE+) and matched them by age and sex with 31 patients without NP‐AEs (AE−). All participants underwent resting‐state EEG within 30 days before LEV. We compared relative power spectral density (PSD) and weighted phase lag index (wPLI) connectivity‐derived graph‐theoretical metrics (clustering coefficient, global efficiency, path length, modularity, node strength) using linear mixed‐effects models. Baseline variables showing significant between‐group differences were included in an elastic‐net penalized logistic regression model. Model performance was evaluated using nested cross‐validation and permutation testing (1000 permutations). Results: Relative PSD showed no differences between groups. The AE+ group showed higher baseline theta‐band wPLI‐derived clustering coefficient ( p = .032), characteristic path length ( p = .033), and node strength ( p = .03) than AE−. In the elastic net model, theta‐band graph‐theoretical metrics predicted NP‐AE occurrence with an accuracy of .71 (95% confidence interval [CI] = .60–.82) and an area under the curve of .71 (95% CI = .57–.83). Permutation testing confirmed that model discrimination exceeded chance level ( p = .003). Significance: Baseline theta‐band qEEG functional network organization emerged as a significant neurophysiological predictor of LEV‐related NP‐AEs. These findings suggest that pretreatment EEG may capture a neurophysiological vulnerability phenotype associated with LEV tolerability, supporting the potential role of network‐level biomarkers in guiding individualized treatment decisions.
- Open Access
- 7 May 2024
- Published by Elsevier in Clinical Neurophysiology
- Vol. 163, 152-159
Quantitative EEG analysis of brivaracetam in drug-resistant epilepsy: A pharmaco-EEG study
- 7 May 2024
- Published by Elsevier in Clinical Neurophysiology
- Vol. 163, 152-159
Open AccessQuantitative EEG analysis of brivaracetam in drug-resistant epilepsy: A pharmaco-EEG study
- Open Access
- 5 April 2023
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 378, 578084
Anti-LGI1 encephalitis: A family affair
- 5 April 2023
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 378, 578084
Open AccessAnti-LGI1 encephalitis: A family affair